SCHEMBL5953508

SCHEMBL5953508

C#CCN(C)CC1=Cc2ccccc2Oc2ccc(C(C)(C)C)cc21

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PYCR1 P32322 11/20 0.37
LMNA P02545 2/20 0.37
CYP3A4 P08684 2/20 0.37
MAOA P21397 2/20 0.37
USP2 O75604 1/20 0.37
TSHR P16473 1/20 0.37
MAOB P27338 1/20 0.37
ALDH1A1 P00352 1/20 0.36
BLM P54132 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP1A2 P05177 2/20 0.34
CYP2C19 P33261 2/20 0.34
DRD2 P14416 2/20 0.33
DRD4 P21917 2/20 0.33
TP53 P04637 1/20 0.33
CYP2D6 P10635 1/20 0.33
MAPT P10636 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CYP19A1 P11511 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Omigapil SCHEMBL333032 0.85 PYCR1 (0.45) PYCR1LMNACYP3A4MAOAUSP2
Omigapil SCHEMBL29377962 0.85 PYCR1 (0.45) PYCR1LMNACYP3A4MAOAUSP2
SCHEMBL5953775 0.83 PYCR1 (0.45) PYCR1LMNACYP3A4MAOAUSP2
SCHEMBL5953497 0.80 PYCR1 (0.46) PYCR1LMNACYP3A4MAOAUSP2
SCHEMBL5953640 0.78 PYCR1 (0.45) PYCR1LMNACYP3A4MAOAUSP2
Omigapil SCHEMBL978230 0.76 PYCR1 (0.40) PYCR1LMNACYP3A4MAOAUSP2
Omigapil SCHEMBL29369408 0.76 PYCR1 (0.40) PYCR1LMNACYP3A4MAOAUSP2
Omigapil SCHEMBL5953610 0.76 PYCR1 (0.40) PYCR1LMNACYP3A4MAOAUSP2
Omigapil SCHEMBL5953608 0.76 PYCR1 (0.40) PYCR1LMNACYP3A4MAOAUSP2
Omigapil SCHEMBL978229 0.76 PYCR1 (0.40) PYCR1LMNACYP3A4MAOAUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060100269-A1 Use of 10-aminoaliphatyl-dibenz[b,f]oxepines for the treatment of degenerative ocular disorders LAMBROU GEORGE N 2006-05-11 US claimed
EP-1589963-A1 USE OF 10-AMINOALIPHATYL-DIBENZ B,F OXEPINES FOR THE TR EATMENT OF DEGENERATIVE OCULAR DISORDERS Novartis AG (CH) 2005-11-02 EP claimed
WO-2004066993-A1 USE OF 10-AMINOALIPHATYL-DIBENZ[B,F]OXEPINES FOR THE TREATMENT OF DEGENERATIVE OCULAR DISORDERS NOVARTIS AG (CH) 2004-08-12 WO claimed
EP-0726265-B1 10-Aminoaliphatyl-dibenz(b,f)oxepins with antineurodegenarative activity NOVARTIS AG (CH) 2001-07-25 EP claimed
US-20060100269-A1 Use of 10-aminoaliphatyl-dibenz[b,f]oxepines for the treatment of degenerative ocular disorders LAMBROU GEORGE N 2006-05-11 US disclosed
EP-1589963-A1 USE OF 10-AMINOALIPHATYL-DIBENZ B,F OXEPINES FOR THE TR EATMENT OF DEGENERATIVE OCULAR DISORDERS Novartis AG (CH) 2005-11-02 EP disclosed
WO-2004066993-A1 USE OF 10-AMINOALIPHATYL-DIBENZ[B,F]OXEPINES FOR THE TREATMENT OF DEGENERATIVE OCULAR DISORDERS NOVARTIS AG (CH) 2004-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100269-A1 Use of 10-aminoaliphatyl-dibenz[b,f]oxepines for the treatment of degenerative ocular disorders DBH, MAOB, AADAT PYCR1 1050/4885LMNA 3703/4885CYP3A4 2574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.